AxoGen’s revenue increased from $2 million in 2012’s second quarter to $2.9 million. Company executives attributed the gain to an increased number of facilities using AxoGen’s products.
The company’s net loss jumped from $3.1 million to $6.9 million, due in part to increased interest costs. The company paid $1.8 million in interest added to the note after having paid no interest the year prior.
More Articles on Devices:
Aesculap’s Quintex Anterior Cervical Spine Plating System Now Available
SpineVision Names Ken Yamada as US Subsidiary COO
Orthozon Technologies Launches Lumiere Retractor for Minimally Invasive Discectomy
